Coca-Cola has struggled to integrate its $5.6 billion purchase of BodyArmor with Powerade, which led to more “disruption in the short-term” than expected, according to CEO James Quincey.
Body Armor’s sales declined in the latest quarter.
The Atlanta-based Coca-Cola is optimistic that BodyArmor will eventually complement Powerade, its other big offering in the sports-drink category, as it aims to better compete against industry heavyweight, Pepsi-owned Gatorade.
BodyArmor’s purchase is the largest acquisition in Coca-Cola’s history.
In 2018, Coca-Cola first paid an undisclosed sum for a 15% share in BodyArmor, which had revenues of around $250 million.
That amount increased to more than $1 billion in 2021 when it acquired the remaining shares of brand to increase the variety of beverages it offers.
Through the use of coconut water, low sodium and high potassium levels, the lack of artificial colors, and the addition of sugar in place of high fructose corn syrup, the fast-growing, healthier sports drink gained popularity among consumers.
The purchase of BodyArmor by Coca-Cola led to a big bet that the beverage would play a key role in building out its liquid offerings and repositioning the business into a “total beverage company.”
Coca-Cola’s U.S. sports-drink market share had slipped in recent months. Still, the Coke chief remains optimistic this year will be a turning point for BodyArmor.


Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal
Select Water Solutions Shares Surge on $700 Million Pilot Water Deal
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals
Solidigm Eyes $150 Billion IPO as SK Hynix Expands AI Storage Push
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue
European Stocks Fall as Bond Yields and Geopolitical Risks Weigh
NBA Returns to China with Alibaba Partnership and Historic Macau Games
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
Asian Currencies Mixed as Dollar Holds Near Two-Month High
U.S. Treasury Yields Surge as 30-Year Hits 22-Year High
Trump Draws Cheers at Ryder Cup as U.S. Trails Europe After Opening Day
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
FDA Weighs Safety Standards for Psychedelic Therapies
U.S. Eases Iran Team Travel Restrictions Ahead of Seattle World Cup Match
OpenAI to Preview GPT-6 Cyber AI Model for Cybersecurity 



